Epoetin Alfa BS JCR
Epoetin alfa and zeta biosimilar developed by JCR Pharmaceuticals. Reference product Eprex (Epogen and Procrit in the United States).
Brands by market: Epoetin Alfa BS [JCR] (Japan) · Commercial partner or holder: JCR Pharmaceuticals
FDAnot listed
EMAnot listed
PMDAJan 2010approved
HCnot listed
CDSCOnot listed
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
PMDA
Japan · Epoetin Alfa BS [JCR]
Pharmaceuticals and Medical Devices Agency and MHLWApprovedBrand
Epoetin Alfa BS [JCR]
Holder or applicant
JCR Pharmaceuticals
Pathway
Biosimilar (MHLW approval on PMDA review)
Approved
Jan 2010
Indications as licensed
Renal anaemia on dialysis; anaemia of prematurity
Presentations
750, 1,500 and 3,000 IU syringes
Note
The INN in Japan is epoetin kappa; reference product Espo. The second biosimilar approved in Japan.
Source
S020
HC
Canada
Not listed by HC.
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- PMDAJan 2010Approved by MHLW
Sources
S020PMDA, list of approved biosimilar products in Japan (as of July 2026) Primary (regulator)
Planning epoetin alfa and zeta biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.